Skip to main content
SpringerLink
Log in
Book cover

Viral Hepatitis: Chronic Hepatitis C pp 159–165Cite as

Management of Interferon-Free Direct-Acting HCV Antiviral Therapy Failure

  • Chapter
  • First Online:

  • 498 Accesses

Abstract

Chronic hepatitis C is one of the major causes of chronic liver disease worldwide with a progressive course that leads to the development of liver cirrhosis, liver failure, and hepatocellular carcinoma if remains untreated. The landscape of chronic hepatitis C treatment has evolved rapidly since 2011 with the arrivals of multiple combinations of direct-acting antiviral (DAA) therapies with the excellent sustained virological response, in the 90%. Despite the outstanding efficacy, antiviral resistance and treatment failure still remain in a small fraction of patients in the current direct-acting antiviral therapies. Recently approved DAAs and future combination therapies focus on targeting the viral resistance and treatment failure using complementary antiviral regimens.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. World Health Organization. Hepatitis C. Media centre. Fact sheet; Oct 2017.

    Google Scholar 

  2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271–8.

    Article  Google Scholar 

  3. Pawlotsky J-M, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007;132(5):1979–98.

    Article  CAS  Google Scholar 

  4. Hassany M, Elsharkwawy A. Chapter 6: HCV treatment failure in the era of DAAs. In: Allam N, editor. Advances in treatment of hepatitis C and B, Infectious diseases. London: IntechOpen; 2017. p. 1–15.

    Google Scholar 

  5. Rockstroh J. Global implementation of hepatitis C (HCV) treatment: what are the successes, what are the remaining challenges? EASL; 2017.

    Google Scholar 

  6. Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol. 2016;22:432–8.

    Article  Google Scholar 

  7. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023–35.

    Article  CAS  Google Scholar 

  8. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.

    Article  CAS  Google Scholar 

  9. Gy I, Dieterich DT. Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol Hepatol. 2012;8:727–65.

    Google Scholar 

  10. Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–32.

    Article  Google Scholar 

  11. European Association for Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.

    Article  Google Scholar 

  12. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Branccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxi A, Bbudieri S, Andreoni M, Angelioi M, Perno CF, Ceccherini-Siberstein F, HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514–28.

    Article  Google Scholar 

  13. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 14 Nov 2017.

  14. Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913–20.

    Article  CAS  Google Scholar 

  15. Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015;62:S220.

    Article  Google Scholar 

  16. Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015;62:S221.

    Article  Google Scholar 

  17. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.

    Article  Google Scholar 

  18. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59(12):1666–74.

    Article  CAS  Google Scholar 

  19. Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, et al. Long-tern persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitors, ledipasvir, without sofosbuvir. Antivir Ther. 2018;23(3):229–38.

    Article  CAS  Google Scholar 

  20. Zeuzem S, Rockstroh JK, Kwo PY, et al. Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)-infected patients: integrated analysis of phase 2-3 trials. AASLD, Nov 13–17. San Francisco, CA; 2015.

    Google Scholar 

  21. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.

    Google Scholar 

  22. Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–46.

    Google Scholar 

  23. Wedemeyer H, et al. Safety and Efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct acting antiviral regimen (C-SURGE). 52nd EASL; Amsterdam, Netherlands; Apr 19–23, 2017. Abstract PS-15.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA

    Ky-Dieu Tran, Abdulmajeed A. Albarrak & Veysel Tahan

Authors
  1. Ky-Dieu Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdulmajeed A. Albarrak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Veysel Tahan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Veysel Tahan .

Editor information

Editors and Affiliations

  1. ESCMID Study Group for Viral Hepatitis (ESGVH), Istanbul, Turkey

    Resat Ozaras

  2. Infectious Diseases Department, Hôtel Dieu Hospital, University of Paris, Paris, France

    Dominique Salmon-Ceron

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tran, KD., Albarrak, A.A., Tahan, V. (2019). Management of Interferon-Free Direct-Acting HCV Antiviral Therapy Failure. In: Ozaras, R., Salmon-Ceron, D. (eds) Viral Hepatitis: Chronic Hepatitis C. Springer, Cham. https://doi.org/10.1007/978-3-030-03757-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03757-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03756-7

  • Online ISBN: 978-3-030-03757-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation